3 recruiting, 2 active not recruiting. 5 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 3, Active not recruiting 2 |
| Phase 2 | 4 | Recruiting 3, Active not recruiting 1 |
Follow Supportive care measures: new trials by email Literature Review of Supportive care measures trials Research Report on Supportive care measures
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) Sacituzumab tirumotecan, Rescue medication, Supportive care measures - Non-Muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 32 | 2024-12-20 | 2026-10-15 |
| A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) Sacituzumab tirumotecan, Enfortumab Vedotin, Pembrolizumab - Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 38 | 2024-07-17 | 2026-02-18 |
| A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin - Colorectal Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 220 | 2024-06-20 | 2026-10-29 |
| Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008) Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures - Non-small Cell Lung Cancer, Solid Tumors | Phase 1 | Active not recruiting | Merck Sharp & Dohme LLC | 30 | 2023-10-26 | 2026-09-02 |
| A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) Paclitaxel, Irinotecan, Pembrolizumab - Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 230 | 2023-05-16 | 2026-10-07 |
Parkinson Disease 4, Autosomal Dominant Lewy Body (3) · Biliary Tract Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Non-Muscle Invasive Bladder Neoplasms (1)
United States (4) · Canada (3) · Italy (3) · Japan (3) · South Korea (3) · Spain (3) · Taiwan (3) · United Kingdom (3) · Chile (2) · China (2) · France (2) · Netherlands (2) · Switzerland (2) · Turkey (Türkiye) (2) · Australia (1)
2023 (3)